Table 1.
Summary of antibody responses and specific B-cells in CVID and XLA patients
| HD n = 28 | HD T0 vs T1 | CVID n = 41 | CVID T0 vs T1 | CVID vs HD (T1) | XLA n = 6 | XLA T0 vs T1 | XLA vs HD (T1) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | IQR (25th–75th) | P value | Median | IQR (25th–75th) | P value | P value | Median | IQR (25th–75th) | P value | P value | |
| SARS-Cov-2 antibodies | |||||||||||
| IgG OD ratio, T0 | 0.10 | 0.00–0.15 | < 0.0001 | 0.12 | 0.07–0.24 | < 0.0001 | < 0.0001 | 0.15 | 0.11–0.16 | > 0.999 | < 0.0001 |
| IgG OD ratio, T1 | 13.00 | 11-.00–12.00 | 0.39 | 0.13–5.25 | 0.12 | 0.10–0.19 | |||||
| IgM µg/mL, T0 | 0.55 | 0–1.24 | 0.0014 | 0 | 0–0.42 | 0.052 | < 0.0001 | 0.00 | – | – | 0.004 |
| IgM µg/mL, T1 | 2.20 | 1.13–4.40 | 0.14 | 0.00–0.92 | 0.00 | – | |||||
| IgA OD ratio, T0 | 0 | 0.2–0.3 | P < 0.0001 | 0.05 | 0.04–0.11 | 0.070 | < 0.0001 | 0.13 | 0.05–0.22 | 0.562 | < 0.0001 |
| IgA OD ratio, T1 | 9 | 11–13 | 0.07 | 0.04–0.20 | 0.05 | 0.04–0.14 | |||||
| HD n = 28 | HD T0 vs T1 | CVID n = 26 | CVID T0 vs T1 | CVID vs HD (T1) | XLA n = 6 | XLA T0 vs T1 | XLA vs HD (T1) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | IQR (25th–75th) | P value | Median | IQR (25th–75th) | P value | P value | Median | IQR (25th–75th) | P value | P value | |
| Spike-specific cells | |||||||||||
| MBC S + %, T0 | 0.21 | 0.13–0.33 | 0.001 | 0.05 | 0–0.15 | 0.19 | < 0.0001 | 0 | 0–0 | – | < 0.0001 |
| MBC S + %, T1 | 0.44 | 0.21–0.65 | 0.08 | 0–0.2 | 0 | 0–0 | – | ||||
| MBC S + + %, T0 | 0 | 0–0.002 | < 0.0001 | 0 | 0–0 | 0.06 | < 0.0001 | 0 | 0–0 | – | 0.0004 |
| MBC S + + %, T1 | 0.016 | 0.005–0.04 | 0 | 0–0.002 | 0 | 0–0 | – | ||||
| Activated MBC S + T0 | 0 | 0–0 | 0.06 | 0 | 0–0 | – | < 0.0001 | 0 | 0–0 | – | < 0.0001 |
| Activated MBC S + T1 | 0 | 0–0.46 | 0 | 0–0 | 0 | 0–0 | – | ||||
| Activated MBC S + + T0 | 0.0 | 0–0 | 0.030 | 0 | 0–0 | – | < 0.0001 | 0 | 0–0 | – | < 0.0001 |
| Activated MBC S + + T1 | 0.21 | 0–0.65 | 0 | 0–0 | 0 | 0–0 | – | ||||
| ATM S + %, T0 | 0 | 0–0 | 0.0001 | 0.0 | 0–0 | 0.019 | 0.43 | 0 | 0–0 | – | 0.08 |
| ATM S + %, T1 | 0.06 | 0–0.35 | 0.0 | 0–0.31 | 0 | 0–0 | – | ||||
| AMT S + + %, T0 | 0 | 0–0 | 0.250 | 0 | 0–0 | > 0.999 | 0.4 | 0 | 0–0 | – | > 0.999 |
| ATM S + + %, T1 | 0 | 0–0 | 0 | 0–0 | 0 | 0–0 | – | ||||
| PB S + %, T0 | 0 | 0–0 | < 0.0001 | 0 | 0–0 | 0.001 | 0.027 | 0 | 0–0 | > 0.999 | 0.0006 |
| PB S + %, T1 | 1.61 | 0.67–2.7 | 0.72 | 0–1.81 | 0 | 0–0.25 | |||||
| PB S + + %, T0 | 0 | 0–0 | < 0.0001 | 0 | 0–0 | 0.125 | 0.005 | 0 | 0–0 | > 0.999 | 0.17 |
| PB S + + %, T1 | 0.15 | 0–0.51 | 0 | 0–0 | 0 | 0–0.25 | |||||
| RBD + %, T0 | 1 | 0–3 | < 0.0001 | 0–0 | 0–0 | – | < 0.0001 | 0–0 | 0–0 | – | < 0.0001 |
| RBD + %, T1 | 16 | 4–39.75 | 0–0 | 0–0 | – | 0–0 | 0–0 | – | |||
| Spike-specific T-cells (IFN-g SFU × 106 cells) T0 | 2.5 | 0–68.7 | 0.041 | 0 | 0–9 | 0.151 | 0.001 | 37.5 | 0–50.5 | 0.041 | 0.937 |
| Spike-specific T-cells (IFN-g SFU × 106 cells) T1 | 115 | 70–250 | 7 | 0–35 | 152.5 | 41.2–185 | |||||